A handheld device for diagnosing the early signs of osteoporosis could be available for clinical use within five years.
The technology is currently being refined and tested at the University of Southampton with support from the Engineering and Physical Sciences Research Council (EPSRC). The original concept was invented at the University of California, Santa Barbara.
Unlike existing methods of assessing bone fragility, which measure bone density using X-rays, the device is designed to measure the ability of bone tissue to prevent small cracks growing into full-blown fractures.
It does this by pressing a microscopic needle a tiny distance into the top layer of bone. Measured electronically, the amount of penetration indicates how fragile the bone tissue is and therefore the risk of experiencing an osteoporotic fracture later in life.
Osteoporosis is often referred to as fragile bone disease. However, for many sufferers, the first indication that they have the condition is when they actually sustain a fracture.
Drugs can slow or arrest the development of the disease, but the condition may already be quite advanced by the time the first break has happened. Doctors can estimate an individual’s risk of fracturing by using bone-density measurements and other factors such as age, gender, smoking and any history of fracturing. But the new microindentation technology affordably delivers a fundamentally different measurement that has huge potential to refine such an evaluation.
A normal reading might see the needle sink into the bone by around 20 micrometres (0.02 mm); a reading of 40 micrometres might indicate a significant risk of fracture.
“As the population ages and life expectancy rises in the decades ahead, the cost of treating osteoporotic fractures will increase,” says Professor Philipp Thurner of the University of Southampton, who is leading the project. “One in three women aged over 50 is forecast to experience an osteoporotic fracture in her lifetime and, globally, treatment costs are forecast to reach over US$130 billion by 2050. The potential improvement in assessing osteoporosis and future fracture risk offered by this new technology could reduce the burden of broken bones for individuals, healthcare systems and the economy.
The Latest on: Osteoporosis
- HPA talks prevention on World Osteoporosis Dayon October 20, 2019 at 9:03 am
On World Osteoporosis Day yesterday, the Health Promotion Administration (HPA) said that on average, 12.3 percent of people aged 65 to 74 in Taiwan have osteoporosis, and suggested three preventive ...
- World Osteoporosis Day: Tips to Keep The Disease at Bayon October 20, 2019 at 5:21 am
World Osteoporosis Day is a global campaign which is observed on October 20 every year. It is celebrated to spread awareness about the importance of good bone health, the importance of the day, and ...
- Why your aching joints could be a sign of osteoporosison October 19, 2019 at 3:39 pm
Visakhapatnam: Osteoporosis or the condition of weak and brittle bones is a growing global problem that affects one out of three women and one out of five men over the age of 50. World Osteoporosis ...
- World Osteoporosis Day: Focus on ‘Emotional Aspects’on October 19, 2019 at 4:27 am
World Osteoporosis Day is celebrated on 20 th October every year Its main objective is to raise awareness about osteoporosis worldwide This campaign could substantially reduce the global burden of ...
- Osteoporosis is not an old age problemon October 19, 2019 at 1:40 am
Strange as that may sound, it’s a sign of of the bones becoming brittle, fragile and prone to breakage easily, which marks the onset of osteoporisis. While osteoporosis may be experienced on or after ...
- IOF: A Fracture Every 3 Seconds Worldwide - That's Osteoporosison October 18, 2019 at 5:07 pm
Lo Lan broke her hip after tripping over a loose carpet in her home. Both women have something in common. They were unaware that they had osteoporosis, the disorder which causes bones to become weak ...
- EU Panel Backs Nasal Glucagon for Hypoglycemia; Romosozumab for Osteoporosison October 18, 2019 at 2:10 pm
The committee also gave a thumbs up to romosozumab (Evenity, UCB Pharma SA) for treatment of postmenopausal women with severe osteoporosis at high risk of fracture. The FDA approved Baqsimi in July.
- Awareness event conducted at CMC Vellore on World Osteoporosis Dayon October 18, 2019 at 10:29 am
The department of endocrinology at Christian Medical College, in collaboration with the departments of geriatrics, orthopedics, physical medicine and dietetics, organised an event in commemoration of ...
- EVENITY® (Romosozumab) Receives Positive CHMP Opinion For The Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fractureon October 17, 2019 at 10:00 pm
EVENITY is a novel bone-builder with a dual effect that increases bone formation and to a lesser extent reduces bone resorption (or bone loss). "After a fracture, postmenopausal women with ...
- Growth of Osteoporosis Drugs Market to be Impacted by Development of Transdermal Drug Delivery System | Technavioon October 16, 2019 at 8:30 am
The report, global osteoporosis drugs market has been added to Technavio’s catalog. It provides a comprehensive analysis of the market, including its global and regional market share as well as market ...
via Google News and Bing News